Literature DB >> 4149286

Does levodopa alter depression and psychopathology in Parkinsonism patients?

G G Marsh, C H Markham.   

Abstract

Twenty-seven Parkinsonism patients and 31 controls, matched for age and verbal IQ, were tested on an objectively scored personality test (Minnesota Multiphasic Personality Inventory) at the beginning of the patients' levodopa therapy and three months later. Patients, but not the controls, were retested after 15 months of levodopa treatment. The patients, all of whom were intact intellectually, obtained MMPI scores indicating moderate depression before beginning levodopa treatment. There was no test evidence to indicate that levodopa significantly increased or decreased the amount of depression in the patients after three or 15 months of levodopa. The patient group, however, significantly increased their Index of Psychopathology (Ip) score after 15 months of levodopa but not after three months.

Entities:  

Mesh:

Substances:

Year:  1973        PMID: 4149286      PMCID: PMC1083592          DOI: 10.1136/jnnp.36.6.925

Source DB:  PubMed          Journal:  J Neurol Neurosurg Psychiatry        ISSN: 0022-3050            Impact factor:   10.154


  24 in total

1.  Changes in MMPI scale scores and an index of psychopathology following unilateral temporal lobectomy for epilepsy.

Authors:  M J Meier; L A French
Journal:  Epilepsia       Date:  1965-09       Impact factor: 5.864

2.  Depressive symptoms in Parkinson patients referred for thalamotomy.

Authors:  J W Warburton
Journal:  J Neurol Neurosurg Psychiatry       Date:  1967-08       Impact factor: 10.154

3.  Modification of Parkinsonism--chronic treatment with L-dopa.

Authors:  G C Cotzias; P S Papavasiliou; R Gellene
Journal:  N Engl J Med       Date:  1969-02-13       Impact factor: 91.245

4.  L-dopa in postencephalitic parkinsonism.

Authors:  D B Calne; G M Stern; D R Laurence; J Sharkey; P Armitage
Journal:  Lancet       Date:  1969-04-12       Impact factor: 79.321

5.  Depression during L-dopa treatment.

Authors:  A M Wagshul; R B Daroff
Journal:  Lancet       Date:  1969-09-13       Impact factor: 79.321

6.  Treatment of parkinsonism with L-dopa (study of 105 patients).

Authors:  H L Klawans; J S Garvin
Journal:  Dis Nerv Syst       Date:  1969-11

7.  Reversal of central anticholinergic syndrome in man by physostigmine.

Authors:  R C Duvoisin; R Katz
Journal:  JAMA       Date:  1968-11-25       Impact factor: 56.272

8.  Treatment of parkinsonism with levodopa.

Authors:  M D Yahr; R C Duvoisin; M J Schear; R E Barrett; M M Hoehn
Journal:  Arch Neurol       Date:  1969-10

9.  L-Dopa (L-3,4-dihydroxyphenylanine)--its clinical effects in parkinsonism.

Authors:  M D Yahr; R C Duvoisin; M M Hoehn; M J Schear; R E Barrett
Journal:  Trans Am Neurol Assoc       Date:  1968

10.  Treatment of Parkinson's syndrome with L dihydroxyphenylalanine (levodopa).

Authors:  F McDowell; J E Lee; T Swift; R D Sweet; J S Ogsbury; J T Kessler
Journal:  Ann Intern Med       Date:  1970-01       Impact factor: 25.391

View more
  25 in total

Review 1.  Potential mechanisms underlying anxiety and depression in Parkinson's disease: consequences of l-DOPA treatment.

Authors:  Karen L Eskow Jaunarajs; Mariana Angoa-Perez; Donald M Kuhn; Christopher Bishop
Journal:  Neurosci Biobehav Rev       Date:  2010-07-06       Impact factor: 8.989

Review 2.  Neuropsychological aspects of Parkinson's disease.

Authors:  S A Raskin; J C Borod; J Tweedy
Journal:  Neuropsychol Rev       Date:  1990-09       Impact factor: 7.444

3.  Methylphenidate : a treatment for Parkinson's disease?

Authors:  David Devos; Caroline Moreau; Arnaud Delval; Kathy Dujardin; Luc Defebvre; Regis Bordet
Journal:  CNS Drugs       Date:  2013-01       Impact factor: 5.749

Review 4.  Neuropsychiatric aspects of Parkinson's disease: recent advances.

Authors:  Laura Marsh; Ariel Berk
Journal:  Curr Psychiatry Rep       Date:  2003-05       Impact factor: 5.285

Review 5.  Parkinson's disease and levodopa. A five-year follow-up and review.

Authors:  C H Markham; L J Treciokas; S G Diamond
Journal:  West J Med       Date:  1974-09

6.  Major depression in Parkinson's disease and the mood response to intravenous methylphenidate: possible role of the "hedonic" dopamine synapse.

Authors:  R Cantello; M Aguggia; M Gilli; M Delsedime; I Chiardò Cutin; A Riccio; R Mutani
Journal:  J Neurol Neurosurg Psychiatry       Date:  1989-06       Impact factor: 10.154

Review 7.  Anti-parkinsonian drugs today.

Authors:  N P Quinn
Journal:  Drugs       Date:  1984-09       Impact factor: 9.546

8.  The pattern of depressive symptoms varies with progression of Parkinson's disease.

Authors:  S J Huber; D L Freidenberg; G W Paulson; E C Shuttleworth; J A Christy
Journal:  J Neurol Neurosurg Psychiatry       Date:  1990-04       Impact factor: 10.154

9.  Parkinson's disease and depression: psychometric properties of the Beck Depression Inventory.

Authors:  B E Levin; M M Llabre; W J Weiner
Journal:  J Neurol Neurosurg Psychiatry       Date:  1988-11       Impact factor: 10.154

10.  Depression in Parkinson disease: a disabling but neglected factor.

Authors:  R Cantello; A Riccio; L Scarzella; D Leotta; B Bergamasco
Journal:  Ital J Neurol Sci       Date:  1984-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.